6/4
04:28 pm
olma
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
6/4
08:04 am
olma
Olema Pharmaceuticals, Inc. (NASDAQ: OLMA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $30.00 price target on the stock.
High
Report
Olema Pharmaceuticals, Inc. (NASDAQ: OLMA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $30.00 price target on the stock.
5/28
07:03 am
olma
Olema Oncology to Participate in Upcoming Investor Conferences in June
Low
Report
Olema Oncology to Participate in Upcoming Investor Conferences in June
5/24
08:35 am
olma
Olema Pharmaceuticals (NASDAQ:OLMA) Is In A Good Position To Deliver On Growth Plans [Yahoo! Finance]
Low
Report
Olema Pharmaceuticals (NASDAQ:OLMA) Is In A Good Position To Deliver On Growth Plans [Yahoo! Finance]
5/15
02:09 pm
olma
Olema Pharmaceuticals, Inc. (NASDAQ: OLMA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $30.00 price target on the stock.
Low
Report
Olema Pharmaceuticals, Inc. (NASDAQ: OLMA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $30.00 price target on the stock.
5/15
07:04 am
olma
Olema Oncology Announces Promising New Data for Palazestrant in Combination with Ribociclib Presented at the 2024 ESMO Breast Cancer Congress [Yahoo! Finance]
Medium
Report
Olema Oncology Announces Promising New Data for Palazestrant in Combination with Ribociclib Presented at the 2024 ESMO Breast Cancer Congress [Yahoo! Finance]
5/15
07:01 am
olma
Olema Oncology Announces Promising New Data for Palazestrant in Combination with Ribociclib Presented at the 2024 ESMO Breast Cancer Congress
Medium
Report
Olema Oncology Announces Promising New Data for Palazestrant in Combination with Ribociclib Presented at the 2024 ESMO Breast Cancer Congress
5/9
03:39 pm
olma
Olema Pharmaceuticals, Inc. (NASDAQ: OLMA) had its price target raised by analysts at HC Wainwright from $25.00 to $28.00. They now have a "buy" rating on the stock.
Low
Report
Olema Pharmaceuticals, Inc. (NASDAQ: OLMA) had its price target raised by analysts at HC Wainwright from $25.00 to $28.00. They now have a "buy" rating on the stock.
5/8
04:05 pm
olma
Olema Oncology Reports First Quarter 2024 Financial Results and Provides Corporate Update [Yahoo! Finance]
Medium
Report
Olema Oncology Reports First Quarter 2024 Financial Results and Provides Corporate Update [Yahoo! Finance]
5/8
04:02 pm
olma
Olema Oncology Reports First Quarter 2024 Financial Results and Provides Corporate Update
Medium
Report
Olema Oncology Reports First Quarter 2024 Financial Results and Provides Corporate Update
5/8
07:08 am
olma
Olema Oncology Announces New Clinical Data for Palazestrant in Combination with Ribociclib to be Presented at the 2024 ESMO Breast Cancer Annual Congress [Yahoo! Finance]
Low
Report
Olema Oncology Announces New Clinical Data for Palazestrant in Combination with Ribociclib to be Presented at the 2024 ESMO Breast Cancer Annual Congress [Yahoo! Finance]
5/8
07:02 am
olma
Olema Oncology Announces New Clinical Data for Palazestrant in Combination with Ribociclib to be Presented at the 2024 ESMO Breast Cancer Annual Congress
Low
Report
Olema Oncology Announces New Clinical Data for Palazestrant in Combination with Ribociclib to be Presented at the 2024 ESMO Breast Cancer Annual Congress
5/2
04:37 pm
olma
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
High
Report
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
5/1
07:02 am
olma
Olema Oncology to Participate in Upcoming Investor Conferences in May
Low
Report
Olema Oncology to Participate in Upcoming Investor Conferences in May
4/10
05:23 pm
olma
FATE, ALPN and RLAY are among after hour movers [Seeking Alpha]
Medium
Report
FATE, ALPN and RLAY are among after hour movers [Seeking Alpha]
4/8
04:30 pm
olma
Olema Oncology to Participate in Canaccord Genuity 2024 Horizons in Oncology Virtual Conference
Low
Report
Olema Oncology to Participate in Canaccord Genuity 2024 Horizons in Oncology Virtual Conference
4/5
12:24 am
olma
Goldman Sachs Predicts Over 120% Rally for These 2 ‘Strong Buy' Stocks [Yahoo! Finance]
Low
Report
Goldman Sachs Predicts Over 120% Rally for These 2 ‘Strong Buy' Stocks [Yahoo! Finance]
4/2
04:29 pm
olma
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
4/2
08:10 am
olma
Olema Pharmaceuticals, Inc. (NASDAQ: OLMA) is now covered by analysts at The Goldman Sachs Group, Inc.. They set a "buy" rating and a $24.00 price target on the stock.
Medium
Report
Olema Pharmaceuticals, Inc. (NASDAQ: OLMA) is now covered by analysts at The Goldman Sachs Group, Inc.. They set a "buy" rating and a $24.00 price target on the stock.